Taro Pharmaceutical Industries Ltd.  

(Public, NYSE:TARO)   Watch this stock  
Find more results for Taro Pharmaceutical Industries Ltd
151.06
-2.07 (-1.35%)
Feb 27 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 150.68 - 153.81
52 week 102.72 - 173.00
Open 153.81
Vol / Avg. 49,617.00/66,207.00
Mkt cap 6.47B
P/E 16.58
Div/yield     -
EPS 9.11
Shares 42.83M
Beta 0.60
Inst. own 15%
May 25, 2015
Q4 2015 Taro Pharmaceutical Industries Ltd Earnings Release (Estimated) - 12:00AM EDT - Add to calendar
Feb 10, 2015
Q3 2015 Taro Pharmaceutical Industries Ltd Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2014
Net profit margin 57.38% 47.57%
Operating margin 63.90% 56.67%
EBITD margin - 59.19%
Return on average assets 41.31% 30.21%
Return on average equity 50.57% 37.93%
Employees 1,342 -
CDP Score - -

Address

14 Hakitor Street, Haifa Bay P.O. Box 10347
HAIFA, 26110
Israel
+972-4-8475700 (Phone)
+972-4-8727165 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Taro Pharmaceutical Industries Ltd. is an Israel-based company, which develops, manufactures and markets market prescription (Rx) and over-the-counter (OTC) products in the United States, Canada and Israel. The Company focuses in semi-solids formulations such as creams and ointments and other dosage forms such as liquids, capsules and tablets, mainly in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. The Company operates through Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company also focuses on providing branded and generic pharmaceuticals in the United Kingdom. Taro International sells active pharmaceutical ingredients and finished dosage form products in countries around the world.

Officers and directors

Dilip Shantilal Shanghvi Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Kalyanasundaram Subramanian Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Michael H. Kalb CPA Interim Chief Financial Officer, Group Vice President, Chief Accounting Officer; Chief Financial Officer of Taro U.S.A.
Age: 42
Bio & Compensation  - Reuters
Stephen Manzano Esq. Interim General Counsel, Vice President of Corporate Compliance
Age: 48
Bio & Compensation  - Reuters
Sunil Mehta Group Vice President, General Manager - Canadian operations
Age: 53
Bio & Compensation  - Reuters
Brant Schofield Vice President - Sales & Marketing, TPHA, U.S.A.
Age: 47
Bio & Compensation  - Reuters
Michele Visosky Vice President - Human Resources, U.S.A.
Age: 47
Bio & Compensation  - Reuters
Mariana Bacalu Group Vice President - Quality Affairs
Age: 61
Bio & Compensation  - Reuters
Michael Teiler Group Vice President - Portfolio Management
Age: 50
Bio & Compensation  - Reuters
Rami Zajicek Esq. Group Vice President, Haifa Site Manager
Age: 49
Bio & Compensation  - Reuters